Paxillin
From Proteopedia
(Difference between revisions)
Line 16: | Line 16: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
- | *Paxillin | + | *Paxillin (residues 1-20) |
**[[4edn]] – hPXN + beta-parvin CH2 domain - human<br /> | **[[4edn]] – hPXN + beta-parvin CH2 domain - human<br /> | ||
**[[2k2r]] – hPXN + beta-parvin CH2 domain - NMR<br /> | **[[2k2r]] – hPXN + beta-parvin CH2 domain - NMR<br /> | ||
**[[2vzg]], [[2vzd]] – hPXN + alpha-parvin C terminal <br /> | **[[2vzg]], [[2vzd]] – hPXN + alpha-parvin C terminal <br /> | ||
- | **[[3rqe]] – hPXN + CCM3<br /> | + | **[[3rqe]], [[3rqg]], [[3rqf]] – hPXN + CCM3<br /> |
+ | **[[1ow6]], [[3gm1]] – hPXN + tyrosine kinase PYK2 focal adhesion targeting domain <br /> | ||
+ | **[[4xgz]], [[4xh2]] – hPXN + antibody<br /> | ||
+ | **[[1ow8]], [[1ow7]] – hPXN + focal adhesion kinase focal adhesion targeting domain <br /> | ||
- | *Paxillin | + | *Paxillin (residues 139-162) |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
**[[4r32]] – cPXN + tyrosine kinase PYK2 focal adhesion targeting domain - chicken<br /> | **[[4r32]] – cPXN + tyrosine kinase PYK2 focal adhesion targeting domain - chicken<br /> | ||
- | **[[1ow6]], [[3gm1]] – hPXN + tyrosine kinase PYK2 focal adhesion targeting domain <br /> | ||
- | **[[1ow7]] – hPXN + focal adhesion kinase focal adhesion targeting domain <br /> | ||
**[[2l6f]] – hPXN + focal adhesion kinase focal adhesion targeting domain - NMR<br /> | **[[2l6f]] – hPXN + focal adhesion kinase focal adhesion targeting domain - NMR<br /> | ||
- | **[[4xh2]] – hPXN + antibody<br /> | ||
**[[2vzi]] – hPXN + alpha-parvin C terminal <br /> | **[[2vzi]] – hPXN + alpha-parvin C terminal <br /> | ||
- | **[[3rqg]] – hPXN + CCM3<br /> | ||
- | *Paxillin proline-rich region | + | *Paxillin (residues 260-281) |
+ | |||
+ | **[[5uwh]] – hPXN + RAN + CRM1 + RANBP1<br /> | ||
+ | **[[3u3f]] – hPXN + tyrosine kinase PYK2 focal adhesion domain<br /> | ||
+ | |||
+ | *Paxillin proline-rich region (residues 45-54) | ||
**[[2o9v]] – hPXN + ponsin SH3 domain<br /> | **[[2o9v]] – hPXN + ponsin SH3 domain<br /> | ||
+ | |||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 07:49, 30 August 2017
|
3D structures of paxillin
Updated on 30-August-2017
References
- ↑ Tumbarello DA, Brown MC, Turner CE. The paxillin LD motifs. FEBS Lett. 2002 Feb 20;513(1):114-8. PMID:11911889
- ↑ Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN, Salgia R. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 1;68(1):132-42. doi: 10.1158/0008-5472.CAN-07-1998. PMID:18172305 doi:http://dx.doi.org/10.1158/0008-5472.CAN-07-1998